title: Comparison of the effects of esomeprazole and fundoplication on airway responsiveness in patients with gastro-oesophageal reflux disease.
abstract: BACKGROUND
  Gastro-oesophageal reflux disease (GORD) is suggested to cause or aggravate several respiratory conditions. Studies with proton pump inhibitors have resulted in only minor improvements in pulmonary outcomes in patients with GORD. It has been speculated that operative treatment of GORD might be more efficient as it also diminishes non-acidic reflux.
  
  
  OBJECTIVE
  To compare the effects of esomeprazole 40 mg bid and fundoplication on airway responsiveness, forced expiratory volume in 1 s (FEV1), exhaled nitric oxide (NO) and respiratory symptoms in patients with moderate-to-severe GORD.
  
  
  METHODS
  Sixty-nine GORD patients had methacholine inhalation challenge performed on them, and FEV1, exhaled NO and respiratory symptoms were measured at baseline, after a 3-month treatment with esomeprazole and 3 months after fundoplication. Primary outcome variable was dose-response slope (DRS), i.e. decline in FEV1 during methacholine challenge divided with the amount of methacholine administered (%/μmol). Pre-defined subgroup analysis was performed among those with concomitant asthma (n = 12).
  
  
  RESULTS
  There was no improvement in DRS, FEV1 or exhaled NO after esomeprazole treatment or fundoplication. Cough and dyspnoea measured with visual analog scale improved with esomeprazole treatment (P < 0.001), and further after fundoplication (P < 0.001). Among those with concomitant asthma, significant improvements in St George Respiratory Questionnaire (SGRQ) scores could be seen after fundoplication.
  
  
  CONCLUSIONS
  Neither esomeprazole treatment nor fundoplication diminishes airway responsiveness or exhaled NO, or improves FEV1 in patients with GORD. Improvements in respiratory symptoms and SGRQ scores after GORD treatments could be detected. However, as this was not a placebo-controlled study, the findings in these secondary endpoints should not be emphasised. ClinicalTrials.cov: NCT00994708.
authors.affiliation: Department of Respiratory Diseases, Terveystalo Hospital, Turku, Finland. toni.kiljander@fimnet.fi
authors.forename: Toni
authors.initials: T
authors.lastname: Kiljander
authors.forename: Tuomo
authors.initials: T
authors.lastname: Rantanen
authors.forename: Ilmo
authors.initials: I
authors.lastname: Kellokumpu
authors.forename: Tiit
authors.initials: T
authors.lastname: Kööbi
authors.forename: Lauri
authors.initials: L
authors.lastname: Lammi
authors.forename: Markku
authors.initials: M
authors.lastname: Nieminen
authors.forename: Tuija
authors.initials: T
authors.lastname: Poussa
authors.forename: Arto
authors.initials: A
authors.lastname: Ranta
authors.forename: Seppo
authors.initials: S
authors.lastname: Saarelainen
authors.forename: Paulina
authors.initials: P
authors.lastname: Salminen
mesh_terms: D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001249:Asthma / Q000209:etiology; D001944:Breath Tests; D016535:Bronchial Hyperreactivity / Q000209:etiology*; D064098:Esomeprazole / Q000627:therapeutic use*; D005260:Female; D005541:Forced Expiratory Volume; D018662:Fundoplication; D005764:Gastroesophageal Reflux / Q000150:complications / Q000188:drug therapy / Q000601:surgery; D006801:Humans; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D000897:Anti-Ulcer Agents; D009569:Nitric Oxide; D064098:Esomeprazole